HRTXHealthcareMicro-Cap

HERON THERAPEUTICS, INC. /DE/ Insider Trading Activity

Every SEC Form 4 insider transaction reported for HERON THERAPEUTICS, INC. /DE/ (HRTX), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are HRTX insiders buying or selling?

HERON THERAPEUTICS, INC. /DE/ insiders reported 12 open-market buys ($15.2M) and 23 sells ($109.7M) across 35 Form 4 filings — a net selling position of $94.5M.

Source: SEC EDGAR Form 4

Key Statistics (as of Aug 12, 2025)

Total Form 4 filings
35
SEC EDGAR
Insider filers
14
Insider buys (12)
$15.2M
Insider sells (23)
$109.7M

Insider sentiment

Net selling

Net insider flow of $94.5M in net selling.

Recent HRTX insider transactions

DateInsiderRoleTypeSharesPriceValue
Aug 12, 2025Rubric Capital Management LP10% OwnerPurchase2.4M$1.50$3.6M
Aug 12, 2025Adam MorganDirectorPurchase1.8M$1.50$2.6M
Nov 21, 2023William P ForbesEVP, Chief Development OfficerPurchase25.0K$1.09$27.3K
Nov 20, 2023William P ForbesEVP, Chief Development OfficerPurchase50.0K$0.94$47.0K
Nov 17, 2023Craig A CollardChief Executive OfficerPurchase150.0K$0.92$138.0K
Nov 17, 2023Ira DuarteEVP, Chief Financial OfficerPurchase85.0K$0.89$75.6K
Jul 25, 2023Adam MorganDirectorPurchase2.5M$1.37$3.4M
May 4, 2022Kimberly ManhardEVP, Drug DevelopmentSale1.5K$4.76$7.2K
Dec 23, 2021Waage ChristianDirectorSale300$9.73$2.9K
Dec 23, 2021Craig A JohnsonDirectorSale250$9.73$2.4K
Sep 23, 2021Waage ChristianDirectorSale300$12.31$3.7K
Sep 23, 2021Craig A JohnsonDirectorSale250$12.30$3.1K
Jun 22, 2021Waage ChristianDirectorSale300$15.20$4.6K
Jun 22, 2021Craig A JohnsonDirectorSale250$15.20$3.8K
May 4, 2021Kimberly ManhardEVP, Drug DevelopmentSale1.5K$17.66$27.0K
Apr 17, 2021Waage ChristianDirectorSale300$17.51$5.3K
Apr 7, 2021Craig A JohnsonDirectorSale250$17.22$4.3K
Jan 15, 2021David Leslie SzekeresEVP, Chief Operating OfficerSale827$18.09$15.0K
Jan 8, 2021David Leslie SzekeresEVP, Chief Operating OfficerSale3.6K$19.66$70.2K
Dec 23, 2020Kimberly ManhardEVP, Drug DevelopmentSale10.0K$20.00$200.0K
May 1, 2020Kimberly ManhardExecutive VP, Drug DevelopmentSale1.2K$13.97$16.2K
Dec 3, 2019Kimberly ManhardExecutive VP, Drug DevelopmentSale24.0K$26.00$624.0K
Oct 7, 2019Kevin TangDirectorPurchase285.7K$17.50$5.0M
Oct 4, 2019Barry D QuartChief Executive OfficerPurchase4.6K$17.50$80.0K
Oct 4, 2019John PoyhonenEVP, Chief Commercial OfficerPurchase5.1K$17.50$90.0K

Showing the 25 most recent of 35 Form 4 filings for HERON THERAPEUTICS, INC. /DE/.

Most active HRTX insiders

  • Kimberly Manhard9 filings
  • Waage Christian5 filings
  • Craig A Johnson4 filings
  • Adam Morgan2 filings
  • Barry D Quart2 filings

Ask anything about HRTX insider activity

Use Trabud's AI agent to query HERON THERAPEUTICS, INC. /DE/'s Form 4 history in plain English — "Show me HRTX CEO purchases this year" or compare it against any other ticker.

Open the AI agent

HRTX insider trading FAQ

Are HERON THERAPEUTICS, INC. /DE/ insiders buying or selling?

Across 35 SEC Form 4 filings, HERON THERAPEUTICS, INC. /DE/ (HRTX) insiders reported 12 open-market purchases totaling $15.2M and 23 sales totaling $109.7M. That is a net selling position of $94.5M.

How many insiders trade HRTX stock?

14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for HERON THERAPEUTICS, INC. /DE/. The most recent filing was accepted on Aug 12, 2025.

Where does Trabud get HRTX insider trading data?

All HRTX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content